NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Phase 2positiveNEO100Positive

AI Analysis

Summary

NeOnc announced that its NEO100 Phase 2a brain cancer study exceeded a historical benchmark by approximately 2.5-fold, demonstrating promising clinical efficacy.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Phase 2a study beat historical benchmark by nearly 2.5x

Importance:7/10

Sentiment:

0.80

Phase 2 dataNEO100brain cancerpositive results

Related Companies

$NTHI

Read the original article

Published by yahoo_finance on August 12, 2026 1:25 PM

Read Original